Karyopharm Therapeutics Inc
SWB:25K
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Karyopharm Therapeutics Inc
SWB:25K
|
US |
|
InspireMD Inc
F:II2
|
IL |
|
C
|
Carrefour SA
XHAM:CAR
|
FR |
|
Verisk Analytics Inc
LSE:0LP3
|
US |
|
MS&AD Insurance Group Holdings Inc
OTC:MSADF
|
JP |
|
Puma SE
OTC:PMMAF
|
DE |
|
Mitsui Chemicals Inc
OTC:MITUY
|
JP |
|
D
|
Dios Fastigheter AB
F:D1F
|
SE |
|
Y
|
Yangtze Optical Fibre and Cable Joint Stock Ltd Co
XBER:1YO
|
CN |
|
Mandarin Oriental International Ltd
F:1C4
|
HK |
Wall St Price Targets
25K Price Targets Summary
Karyopharm Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 25K is 6.63 EUR with a low forecast of 3.43 EUR and a high forecast of 8.15 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 25K's stock price target?
Price Target
6.63
EUR
According to Wall Street analysts, the average 1-year price target for 25K is 6.63 EUR with a low forecast of 3.43 EUR and a high forecast of 8.15 EUR.
What is the Revenue forecast for Karyopharm Therapeutics Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 3 years is 17%.
What is the Gross Profit forecast for Karyopharm Therapeutics Inc?
Projected CAGR
15%
The compound annual growth rate for Gross Profit over the next 3 years is 15%.
